vicl للمتابعه اليوم

[FreeTrader]

Vical beats by $0.06, beats on revs (VICL) 5.50 : Reports Q1 (Mar) loss of $0.16 per share, $0.06 better than the Reuters Estimates consensus of ($0.22); revenues rose 109% year/year to $5.6 mln vs the $3.7 mln consensus. (see also 7:26 comment for more news)

بينفع مضاربه ممكن اليوم

 

[FreeTrader]

اسف ما عدى الفلتر

 

[تريليوني]

Vical beats by $0.06, beats on revs (VICL) 5.50 : Reports Q1 (Mar) loss of $0.16 per share, $0.06 better than the Reuters Estimates consensus of ($0.22); revenues rose 109% year/year to $5.6 mln vs the $3.7 mln consensus. (see also 7:26 comment for more news)

بينفع مضاربه ممكن اليوم

+ هذا الخبر راح يخليه السهم فوق النخل


Vical's DNA Vaccine provides complete protection against avian flu, demonstrates cross-protection against multiple human flu strains in animal studies (VICL) 5.50 : Co announces that it's three-component influenza DNA vaccine candidate provided 100% protection in mice and ferrets against lethal challenges with a highly virulent (Vietnam/1203/2004) H5N1 avian influenza virus in studies conducted by Richard J. Webby, Ph.D., at St. Jude Children's Research Hospital. Additionally, in these and earlier studies in mice, simplified versions of Vical's vaccine candidate using only two of the three components provided high levels of protection against multiple human flu strains and against the H5N1 avian flu strain, which is important because a pandemic could arise from a strain other than H5N1. The studies were part of the co's program to develop a DNA vaccine that protects humans against emerging strains of flu virus that have the potential to cause a pandemic. Based on the results, the co is continuing to advance toward human testing of the pandemic flu DNA vaccine candidate.

 

[سهم مرتاح]

اسف ما عدى الفلتر

كان من افضل الاسهم امس..

 

[الناشئ]

اسف ما عدى الفلتر

للأسف لم يجتز الفلتر